Drugmaker developing abuse-deterrent painkiller

The San Diego company that makes the powerful new prescription painkiller Zohydro is selling off its migraine therapy business to focus on developing abuse-resistant forms of Zohydro.

Zogenix Chief Executive Officer Roger Hawley said the sale will help the company focus on the launch of Zohydro ER while providing capital "to continue the development of two abuse-deterrent formulations" of the opioid.

The company announced in November it would pursue an abuse-deterrent form of the drug.

Health officials around the country worry addicts will crush Zohydro capsules and then snort or inject the drug to get high.

Citing such worries, Massachusetts Gov. Deval Patrick tried to ban the drug, but a blocked the state from enforcing the ban. Patrick has since announced new restrictions on the .

4 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

States revolt against powerful new painkiller

Apr 04, 2014

State officials fighting a well-publicized battle against heroin and prescription drug abuse are revolting against a powerful new painkiller that law enforcement and public health officials fear could worsen ...

Sen. Joe Manchin seeks to block new painkiller

Mar 11, 2014

U.S. Sen. Joe Manchin is calling on the government's top health official to overturn the approval of a powerful painkiller, arguing that the pill Zohydro could add to the national epidemic of prescription drug abuse.

Recommended for you

Expression of privilege in vaccine refusal

21 hours ago

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

Using computers to design drugs

Aug 22, 2014

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

User comments